JP2012526530A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526530A5 JP2012526530A5 JP2012510274A JP2012510274A JP2012526530A5 JP 2012526530 A5 JP2012526530 A5 JP 2012526530A5 JP 2012510274 A JP2012510274 A JP 2012510274A JP 2012510274 A JP2012510274 A JP 2012510274A JP 2012526530 A5 JP2012526530 A5 JP 2012526530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- axl
- amino acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000003463 hyperproliferative effect Effects 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 claims 1
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 claims 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102100031638 Tuberin Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006909 anti-apoptosis Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09006355A EP2270053A1 (en) | 2009-05-11 | 2009-05-11 | Humanized AXL antibodies |
| EP09006355.3 | 2009-05-11 | ||
| EP09006474.2 | 2009-05-13 | ||
| EP09006474 | 2009-05-13 | ||
| PCT/EP2010/056487 WO2010130751A1 (en) | 2009-05-11 | 2010-05-11 | Humanized axl antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015188556A Division JP2016011306A (ja) | 2009-05-11 | 2015-09-25 | ヒト化ａｘｌ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526530A JP2012526530A (ja) | 2012-11-01 |
| JP2012526530A5 true JP2012526530A5 (enExample) | 2013-06-20 |
| JP5909442B2 JP5909442B2 (ja) | 2016-04-26 |
Family
ID=42272537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510274A Expired - Fee Related JP5909442B2 (ja) | 2009-05-11 | 2010-05-11 | ヒト化ａｘｌ抗体 |
| JP2015188556A Pending JP2016011306A (ja) | 2009-05-11 | 2015-09-25 | ヒト化ａｘｌ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015188556A Pending JP2016011306A (ja) | 2009-05-11 | 2015-09-25 | ヒト化ａｘｌ抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8841424B2 (enExample) |
| EP (1) | EP2430050A1 (enExample) |
| JP (2) | JP5909442B2 (enExample) |
| KR (1) | KR20120035145A (enExample) |
| CN (1) | CN102421802B (enExample) |
| AR (1) | AR076564A1 (enExample) |
| AU (1) | AU2010247464B2 (enExample) |
| BR (1) | BRPI1013428A2 (enExample) |
| CA (1) | CA2759836A1 (enExample) |
| IL (1) | IL216147A (enExample) |
| MX (1) | MX2011011825A (enExample) |
| RU (2) | RU2571224C2 (enExample) |
| TW (2) | TWI526223B (enExample) |
| WO (1) | WO2010130751A1 (enExample) |
| ZA (1) | ZA201107529B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120035145A (ko) * | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| US9005926B2 (en) | 2009-10-02 | 2015-04-14 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
| WO2012158551A1 (en) | 2011-05-13 | 2012-11-22 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
| KR20140104944A (ko) * | 2011-06-22 | 2014-08-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-ａｘｌ 항체 및 그의 용도 |
| EP2723377B1 (en) * | 2011-06-22 | 2018-06-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| US9624308B2 (en) * | 2012-11-05 | 2017-04-18 | Pierre Fabre Medicament | Antigen binding proteins |
| ES2665323T7 (es) * | 2012-12-14 | 2023-06-15 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| WO2016091891A1 (en) * | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
| US10208121B2 (en) | 2014-12-18 | 2019-02-19 | Bergen Teknologioverforing As | Anti-Axl antagonistic antibodies |
| GB201506411D0 (en) * | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| US10787517B2 (en) | 2015-05-18 | 2020-09-29 | Agensys, Inc. | Antibodies that bind to AXL proteins |
| EP3297662A4 (en) | 2015-05-18 | 2019-03-13 | Agensys, Inc. | ANTIBODIES BINDING TO AXL PROTEINS |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| US20180326084A1 (en) | 2015-07-10 | 2018-11-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| PL3354729T3 (pl) | 2015-09-24 | 2024-05-20 | Daiichi Sankyo Company, Limited | Przeciwciało anty-garp |
| KR20180126079A (ko) * | 2016-04-15 | 2018-11-26 | 바이오아트라, 엘엘씨 | 항 Axl항체, 항체 단편 및 이의 면역접합체와 이것들의 용도 |
| GB201610902D0 (en) | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| MX2019012464A (es) | 2017-04-20 | 2019-12-11 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. |
| CN110540592B (zh) | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| CN109160941B (zh) * | 2018-09-29 | 2020-09-04 | 未名生物医药有限公司 | 蛋白序列17e11及其用途 |
| RU2678569C1 (ru) * | 2018-10-31 | 2019-01-30 | Гордейчук Владимир Евгеньевич | Способ подавления метастазирования опухолей |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| CN110982791A (zh) * | 2019-12-26 | 2020-04-10 | 百泰生物药业有限公司 | 一种分泌axl抗体的杂交瘤细胞的制备筛选方法 |
| CA3164037A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| KR20230013241A (ko) | 2020-04-08 | 2023-01-26 | 베르겐바이오 에이에스에이 | 항바이러스 요법을 위한 axl 억제제 |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| CA3205570A1 (en) | 2021-01-29 | 2022-08-04 | Chan Hyuk Kim | Fusion molecule having non-inflammatory phagocytosis inducing activity |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| CN115927243A (zh) * | 2022-09-13 | 2023-04-07 | 中山大学 | 一种akt1蛋白的抑制性磷酸化位点及其应用 |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931385A (en) * | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
| DE3900534A1 (de) | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| JP2000511403A (ja) * | 1996-03-20 | 2000-09-05 | イムノメディクス，インコーポレイテッド | 抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用 |
| CA2376192A1 (en) | 1999-06-07 | 2000-12-14 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| EP1382969A1 (en) * | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CA2582683A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
| LT2620450T (lt) | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| AU2006255415B2 (en) * | 2005-06-07 | 2011-10-06 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| EP2170395A1 (en) | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| WO2009062112A2 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
| NZ599628A (en) * | 2007-11-12 | 2013-11-29 | U3 Pharma Gmbh | Axl antibodies |
| KR20120035145A (ko) * | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
-
2010
- 2010-05-11 KR KR1020117026757A patent/KR20120035145A/ko not_active Ceased
- 2010-05-11 TW TW103142582A patent/TWI526223B/zh not_active IP Right Cessation
- 2010-05-11 TW TW099114946A patent/TW201105348A/zh unknown
- 2010-05-11 RU RU2011150183/10A patent/RU2571224C2/ru not_active IP Right Cessation
- 2010-05-11 AU AU2010247464A patent/AU2010247464B2/en not_active Ceased
- 2010-05-11 CN CN201080020597.6A patent/CN102421802B/zh not_active Expired - Fee Related
- 2010-05-11 CA CA2759836A patent/CA2759836A1/en not_active Abandoned
- 2010-05-11 MX MX2011011825A patent/MX2011011825A/es active IP Right Grant
- 2010-05-11 AR ARP100101604A patent/AR076564A1/es unknown
- 2010-05-11 JP JP2012510274A patent/JP5909442B2/ja not_active Expired - Fee Related
- 2010-05-11 WO PCT/EP2010/056487 patent/WO2010130751A1/en not_active Ceased
- 2010-05-11 US US13/320,060 patent/US8841424B2/en not_active Expired - Fee Related
- 2010-05-11 EP EP10718217A patent/EP2430050A1/en not_active Withdrawn
- 2010-05-11 BR BRPI1013428A patent/BRPI1013428A2/pt not_active IP Right Cessation
-
2011
- 2011-10-13 ZA ZA2011/07529A patent/ZA201107529B/en unknown
- 2011-11-03 IL IL216147A patent/IL216147A/en not_active IP Right Cessation
-
2014
- 2014-07-15 US US14/331,709 patent/US20150037323A1/en not_active Abandoned
-
2015
- 2015-09-25 JP JP2015188556A patent/JP2016011306A/ja active Pending
- 2015-11-03 RU RU2015147287A patent/RU2015147287A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526530A5 (enExample) | ||
| RU2015147287A (ru) | Гуманизированные антитела против axl | |
| JP2013531655A5 (enExample) | ||
| JP2008529489A5 (enExample) | ||
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| Hervent et al. | Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics | |
| JP2013165711A5 (enExample) | ||
| JP2018511319A5 (enExample) | ||
| JP2017532005A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| RU2010123888A (ru) | Axl-антитела | |
| JP2016536330A5 (enExample) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2012012402A5 (enExample) | ||
| EA201001874A1 (ru) | Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты | |
| CN120365432A (zh) | 双特异性抗体 | |
| RU2013129450A (ru) | Способ лечения опухолей с применением vegf-специфических антагонистов | |
| JP2018518151A5 (enExample) | ||
| He et al. | A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging | |
| AU2015238264A1 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer | |
| Field et al. | Novel highly specific anti‐periostin antibodies uncover the functional importance of the fascilin 1‐1 domain and highlight preferential expression of periostin in aggressive breast cancer | |
| JP6900051B2 (ja) | Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬 | |
| US20250145708A1 (en) | Epitope of Regulatory T Cell Surface Antigen and Antibody Specifically Binding Thereto | |
| TWI688575B (zh) | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 | |
| CN117062834A (zh) | Gpc3人源化抗体及其应用 |